Cancer Research

The strategic alliance between Merck and the Sarah Cannon Research Institute aims to transform oncology research by deploying a network of over 200 locations and 1,500 oncology physicians. This massive undertaking addresses a fundamental imbalance in modern medicine: while nearly eighty-five

The SOHO-01 trial results highlight that gastrointestinal and skin-related issues such as diarrhea and rash are the most common side effects, which are generally considered manageable by clinicians. On August 24, 2026, Japan’s Ministry of Health, Labour and Welfare reached a landmark decision by

International researchers have identified a five-week chemoradiotherapy protocol that allows four out of five patients to avoid major surgery while maintaining their quality of life. This paradigm shift in oncology marks a departure from the traditional approach, where radical excision was

The persistent failure of conventional neuro-oncology treatments to extend median survival beyond eighteen months has catalyzed a profound transition from targeting individual malignant cells to orchestrating the total disruption of the glioma microenvironment. This shift represents more than just

The scalability of NGSE-Corr suggests that the method becomes increasingly powerful and reliable when applied to large-scale clinical datasets and patient populations. This innovative approach addresses a fundamental limitation in modern medical diagnostics where the push for quantitative data

The historical classification of the PVT1 locus as a non-coding region has been overturned by evidence showing it produces functional proteins that dictate the survival of malignant cells. For decades, the oncology community has viewed the MYC gene as the most frustrating obstacle in cancer